Loading…
Employees: 5,041
Size Zhuzhou Qianjin Pharmaceutical (600479.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $787M, the 2809th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.66 on 6 Nov 2026.
Performance Over six months the shares fell 3.2%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 3.5% over the last twelve months (peer median +1.2%); the operating margin is 11.0% (peer median 7.3%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 2.4× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points above its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.75B | CN¥3.60B | CN¥3.59B | CN¥3.77B | CN¥4.00B |
| Revenue growth | — | 0% | -5% | -6% | — |
| Gross profit | CN¥1.88B | CN¥1.71B | CN¥1.61B | CN¥1.69B | CN¥1.68B |
| EBITDA | n/a | CN¥483M | CN¥401M | CN¥498M | CN¥517M |
| Net income | CN¥357M | CN¥286M | CN¥231M | CN¥320M | CN¥303M |
| Free cash flow | CN¥360M | CN¥361M | CN¥357M | CN¥410M | CN¥725M |
| Capital expenditure | CN¥142M | CN¥124M | CN¥47.3M | CN¥44.0M | CN¥34.4M |
| Total debt | CN¥561M | CN¥559M | CN¥407M | CN¥560M | CN¥700M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600479.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.1% | -0.4% | 6th lowest of 20 |
| 6-month return | -3.2% | -9.5% | 7th highest of 20 |
| Distance from 52-week high | -30.1% | -32.1% | 9th highest of 20 |
| Revenue growth (TTM) | +3.5% | +1.2% | 9th highest of 19 |
| Operating margin | 11.0% | 7.3% | 7th highest of 19 |
| EV / Sales | 1.4× | 2.4× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -1.4% | 2.6% | 5th least demanding of 13 |
| Growth delivered (Del g) | 0.0% | +4.0% | 4th lowest of 13 |
| Hurdle (Req g minus delivered) | -1.4 pp | -1.3 pp | 7th least demanding of 13 |
| ROIC minus cost of capital | +3.8 pp | +0.2 pp | 5th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | 0.6× | 4.9% | +5.3% |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |